References
- Elewski BE. (1998). Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev, 11:415–429.
- Evans EG. (1998). Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol, 38:S32–S36.
- Finch JJ, Warshaw EM. (2007). Toenail onychomycosis: current and future treatment options. Dermatol Ther, 20:31–46.
- Roberts DT. (1999). Onychomycosis: current treatment and future challenges. Br J Dermatol, 141 (Suppl 56):1–4.
- Sigurgeirsson B, Steingrímsson O. (2004). Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol, 18:48–51.
- Gupta AK, Shear NH. (2000). A risk–benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf, 22:33–52.
- Millikan LE, Powell DW, Drake LA. (1999). Quality of life for patients with onychomycosis. Int J Dermatol, 38 (Suppl 2):13–16.
- Effendy I. (1995). Therapeutic strategies in onychomycosis. J Eur Acad Dermatol Venerol, 4:S3–S10.
- Piérard GE, Arrese JE, Quatresooz P, Piérard-Franchimont C. (2007). Emerging therapeutic agents for onychomycosis. Expert Opin Emerg Drugs, 12:345–353.
- Arrese JE, Piérard GE. (2003). Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (Basel), 207:255–260.
- Baran R, Kaoukhov A. (2005). Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol, 19:21–29.
- Murdan S. (2002). Drug delivery to the nail following topical application. Int J Pharm, 236:1–26.
- Bodman MA, Feder L, Nace AM. (2003). Topical treatments for onychomycosis: a historical perspective. J Am Podiatr Med Assoc, 93:136–141.
- Nair AB, Kim HD, Chakraborty B, Singh J, Zaman M, Gupta A et al. (2009). Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci, 98:4130–4140.
- Nair AB, Vaka SR, Sammeta SM, Kim HD, Friden PM, Chakraborty B et al. (2009). Trans-ungual iontophoretic delivery of terbinafine. J Pharm Sci, 98:1788–1796.
- Scher RK. (1996). Onychomycosis: a significant medical disorder. J Am Acad Dermatol, 35:S2–S5.
- Dykes PJ, Thomas R, Finlay AY. (1990). Determination of terbinafine in nail samples during systemic treatment for onychomycoses. Br J Dermatol, 123:481–486.
- Dutet J, Delgado-Charro MB. (2009). In vivo transungual iontophoresis: effect of DC current application on ionic transport and on transonychial water loss. J Control Release, 140:117–125.
- Faergemann J, Zehender H, Denouël J, Millerioux L. (1993). Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol, 73:305–309.
- Hui X, Shainhouse Z, Tanojo H, Anigbogu A, Markus GE, Maibach HI et al. (2002). Enhanced human nail drug delivery: nail inner drug content assayed by new unique method. J Pharm Sci, 91:189–195.